Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK.

Lancet Oncol. 2010 Jan;11(1):21-8. doi: 10.1016/S1470-2045(09)70311-0. Epub 2009 Nov 10. Erratum in: Lancet Oncol. 2010 Jan;11(1):14.

PMID:
19897418
2.

Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?

Bourhis J, Lefebvre JL, Vermorken JB.

Eur J Cancer. 2010 Jul;46(11):1979-89. doi: 10.1016/j.ejca.2010.05.015. Epub 2010 Jun 17. Review.

PMID:
20561781
3.

Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis.

Abdel-Rahman O, Fouad M.

Crit Rev Oncol Hematol. 2015 Feb;93(2):127-35. doi: 10.1016/j.critrevonc.2014.07.005. Epub 2014 Aug 12. Review.

PMID:
25139841
4.

The role of cetuximab in the treatment of squamous cell cancer of the head and neck.

Burtness B.

Expert Opin Biol Ther. 2005 Aug;5(8):1085-93. Review.

PMID:
16050785
5.
6.

Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.

Bernier J, Bonner J, Vermorken JB, Bensadoun RJ, Dummer R, Giralt J, Kornek G, Hartley A, Mesia R, Robert C, Segaert S, Ang KK.

Ann Oncol. 2008 Jan;19(1):142-9. Epub 2007 Sep 4.

7.

Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Greenhalgh J, Bagust A, Boland A, Fleeman N, McLeod C, Dundar Y, Proudlove C, Shaw R.

Health Technol Assess. 2009 Oct;13 Suppl 3:49-54. doi: 10.3310/hta13suppl3/08. Review.

8.
9.

Cetuximab: a review of its use in squamous cell carcinoma of the head and neck.

Frampton JE.

Drugs. 2010 Oct 22;70(15):1987-2010. doi: 10.2165/11205010-000000000-00000. Review.

PMID:
20883055
10.
11.

Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?

Pérez-Soler R.

Oncology (Williston Park). 2003 Nov;17(11 Suppl 12):23-8. Review.

12.

[Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].

Song Q, Li X, Li B.

Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015 Jan;29(1):67-75. Review. Chinese.

PMID:
25966559
13.

Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies.

Petrelli F, Coinu A, Riboldi V, Borgonovo K, Ghilardi M, Cabiddu M, Lonati V, Sarti E, Barni S.

Oral Oncol. 2014 Nov;50(11):1041-8. doi: 10.1016/j.oraloncology.2014.08.005. Epub 2014 Aug 28. Review.

PMID:
25176576
14.

Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis.

Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, Horiot JC, Le Maître A, Pajak TF, Poulsen MG, O'Sullivan B, Dobrowsky W, Hliniak A, Skladowski K, Hay JH, Pinto LH, Fallai C, Fu KK, Sylvester R, Pignon JP; Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group.

Lancet. 2006 Sep 2;368(9538):843-54. Review.

PMID:
16950362
15.
16.
17.

Recent multidisciplinary approach with molecular targeted drugs for advanced head and neck cancer.

Fujii M.

Int J Clin Oncol. 2014 Apr;19(2):220-9. doi: 10.1007/s10147-014-0671-9. Epub 2014 Feb 28. Review.

PMID:
24578179
18.

The role of cetuximab in the management of head and neck cancers.

Kabolizadeh P, Kubicek GJ, Heron DE, Ferris RL, Gibson MK.

Expert Opin Biol Ther. 2012 Apr;12(4):517-28. doi: 10.1517/14712598.2012.667397. Review.

PMID:
22413826
19.

Integrating biologically targeted therapy in head and neck squamous cell carcinomas.

Le QT, Raben D.

Semin Radiat Oncol. 2009 Jan;19(1):53-62. doi: 10.1016/j.semradonc.2008.09.010. Review.

20.

HER2 as a therapeutic target in head and neck squamous cell carcinoma.

Pollock NI, Grandis JR.

Clin Cancer Res. 2015 Feb 1;21(3):526-33. doi: 10.1158/1078-0432.CCR-14-1432. Epub 2014 Nov 25. Review.

Items per page

Supplemental Content

Write to the Help Desk